# ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases

> **NCT07187713** · PHASE4 · RECRUITING · sponsor: **Ace Cells Lab Limited** · enrollment: 300 (estimated)

## Conditions studied

- Hypertensive Nephropathy
- Auto Immune Disorders
- Chronic Kidney Disease
- Chronc Kidney Disease Stage 5
- Chronic Kidney Disease (Stage 3-4)
- Chronic Kidney Disease (Stages 4 and 5)
- Microalbuminuria
- Diabetic Nephropathies

## Interventions

- **DRUG:** ACE Reno

## Key facts

- **NCT ID:** NCT07187713
- **Lead sponsor:** Ace Cells Lab Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-20
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187713, "ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT07187713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*